BF SPIROMAX Vs SYMBICORT TURBOHALER in patients with Persistent Asthma

• Research type

  Research Study

• Full title

  A 12 Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthma

• IRAS ID

  124455

• Contact name

  David Simcock

• Contact email

  david.simcock@bartshealth.nhs.uk

• Sponsor organisation

  Teva Branded Pharmaceutical Products R&D, Inc.

• Eudract number

  2013-000081-11

• Clinicaltrials.gov Identifier

  NCT01803555

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  13/LO/0560

• Date of REC Opinion

  4 Jul 2013

• REC opinion

  Further Information Favourable Opinion